PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation

por Seront, E, Pinto, A, Bouzin, C, Bertrand, L, Machiels, J-P, Feron, O
Publicado 2013

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours

por Seront, E, Boidot, R, Bouzin, C, Karroum, O, Jordan, B F, Gallez, B, Machiels, J-P, Feron, O
Publicado 2013

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

por van Marcke, C., Honoré, N., van der Elst, A., Beyaert, S., Derouane, F., Dumont, C., Aboubakar Nana, F., Baurain, J. F., Borbath, I., Collard, P., Cornélis, F., De Cuyper, A., Duhoux, F. P., Filleul, B., Galot, R., Gizzi, M., Mazzeo, F., Pieters, T., Seront, E., Sinapi, I., Van den Eynde, M., Whenham, N., Yombi, J. C., Scohy, A., van Maanen, A., Machiels, J. P.
Publicado 2021

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

por Geukens, T., Brandão, M., Laenen, A., Collignon, J., Van Marcke, C., Louviaux, I., Demey, W., Van Wambeke, S., Schrijvers, D., Lecomte, S., Mebis, J., Rutten, A., Fontaine, C., Lybaert, W., Aspeslagh, S., Goeminne, J.-C., Van Den Bulck, H., Seront, E., De Backer, L., De Roock, W., Ignatiadis, M., Prenen, H., Van Beckhoven, D., Heijlen, M., Verheezen, J., Rottey, S., Punie, K., de Azambuja, E.
Publicado 2022